Stocks / Investors / rock-springs-capital-management-lp

… 13F portfolio

Rock Springs Capital's portfolio at a glance (Q2 2026 13F)

Rock Springs Capital's latest Form 13F covers Q2 2026 and was filed with the SEC on 2026-08-14. It lists 104 US stock positions worth about $2.0 billion.

The largest holdings are Revolution Medicines Inc (RVMD) at 10.1%, Travere Therapeutics Inc (TVTX) at 6.0%, Eli Lilly & Co (LLY) at 5.8%, Madrigal Pharmaceuticals Inc (MDGL) at 4.6%, Mirum Pharmaceuticals Inc (MIRM) at 4.6% of the portfolio.

Compared with the previous quarter, Rock Springs Capital opened 17 new positions (biggest: Ascendis Pharma A/S, Avalyn Pharmaceuticals Inc (AVLN), Hemab Therapeutics Hldgs Inc (COAG)), sold out of 13 (biggest: Ascendis Pharma A/S, Arcellx Inc, Centessa Pharmaceuticals Plc), added to 39, trimmed 30.

Rock Springs Capital's top 10 holdings, Q2 2026

#HoldingShare of portfolio
1Revolution Medicines Inc (RVMD)10.1%
2Travere Therapeutics Inc (TVTX)6.0%
3Eli Lilly & Co (LLY)5.8%
4Madrigal Pharmaceuticals Inc (MDGL)4.6%
5Mirum Pharmaceuticals Inc (MIRM)4.6%
6Rhythm Pharmaceuticals Inc (RYTM)3.8%
7Kymera Therapeutics Inc (KYMR)2.5%
8Argenx Se - Adr (ARGX)2.4%
9Ascendis Pharma A/S (K08588103)2.2%
10Xenon Pharmaceuticals Inc (XENE)2.0%

94 more positions, with shares, values and each one's history, are in RetailVest Pro.

What Rock Springs Capital bought and sold in Q2 2026

Opened · 17 positions, the biggest:
Ascendis Pharma A/S; Avalyn Pharmaceuticals Inc (AVLN); Hemab Therapeutics Hldgs Inc (COAG)
Added to · 39 positions, the biggest:
Travere Therapeutics Inc (TVTX) (+47% shares); Madrigal Pharmaceuticals Inc (MDGL) (+2% shares); Rhythm Pharmaceuticals Inc (RYTM)
Trimmed · 30 positions, the biggest:
Revolution Medicines Inc (RVMD) (-9% shares); Mirum Pharmaceuticals Inc (MIRM) (-2% shares); Kymera Therapeutics Inc (KYMR) (-9% shares)
Closed · 13 positions, the biggest:
Ascendis Pharma A/S; Arcellx Inc; Centessa Pharmaceuticals Plc

Source: Form 13F filed with the SEC on 2026-08-14 (EDGAR). Start a 7-day free trial to see every position, every change on the quarter and the filing history.

Questions about Rock Springs Capital's 13F

What stocks does Rock Springs Capital own?
As of the Q2 2026 13F filing, Rock Springs Capital's largest US stock holdings are Revolution Medicines Inc (RVMD), 10.1%; Travere Therapeutics Inc (TVTX), 6.0%; Eli Lilly & Co (LLY), 5.8%; Madrigal Pharmaceuticals Inc (MDGL), 4.6%; Mirum Pharmaceuticals Inc (MIRM), 4.6%.
What is Rock Springs Capital buying and selling?
Compared with the previous quarter, Rock Springs Capital opened 17 new positions (biggest: Ascendis Pharma A/S, Avalyn Pharmaceuticals Inc (AVLN), Hemab Therapeutics Hldgs Inc (COAG)), sold out of 13 (biggest: Ascendis Pharma A/S, Arcellx Inc, Centessa Pharmaceuticals Plc), added to 39, trimmed 30.
When will Rock Springs Capital file the next 13F?
13F filings are due 45 days after each quarter ends, so the next one is due by about 2026-11-14.
How current is 13F data?
A 13F shows long US stock and option positions at the end of a quarter and can be up to 45 days old when filed. It doesn't show short positions, cash, bonds or non-US holdings.

Email me when Rock Springs Capital files a new 13F

One email when the next quarterly filing shows up on SEC EDGAR, with what was bought and sold.

We'll only email you about this. Unsubscribe anytime.

How are we doing?